Log in using OpenID

Cytomegalovirus Retinitis Market Analysis By 2023

Cytomegalovirus Retinitis Market - Global
Industry Analysis, Size, Share, Growth, Trends, Single User
and Forecast 2015 - 2023
USD 4315.5
Transparency Market Research
State Tower,
90, State Street, Suite 700.
Albany, NY 12207
United States
[email protected]
Flat 10% Discount!!
Free Customization as per your requirement
You will get Custom Report at Syndicated Report
Report will be delivered with in 15-20 working days
Request Sample
Buy Now
Cytomegalovirus (CMV) Retinitis is caused by cytomegalovirus infection, which is a herpes-type virus that affects the retina of the human eye
among patients having a weak immune system that could be due to conditions such as AIDS, leukemia and/or pregnancy. Symptomatic conditions
include floaters, flashes, and blind spots besides loss of peripheral or blurred vision in the eyes of immune compromised patients.CMV infection
often leads to hemorrhagic retinal inflammation along with vascular distribution. The CMV infection if left untreated spreads from one eye to the
other, eventually leading to visual loss and/or complete blindness. Therefore, prompt diagnosis through blood as well as urine tests besides other
optical tests that involve withdrawal of a small specimen fluid from the infected eye is recommended.
Browse Full Report With TOC:-
Global CMV retinitis market can be segmented on the basis of anti-CMV drugs or anti-infective ophthalmic drugs into Foscarnet, Ganciclovir,
Cidofovir, Fomivirsen and others. In the anti-CMV drugs segment, various off-label drugs are also being used, however many of these drugs have
serious contraindications. In this market segment, one of the key challenges is drug resistance which needs to be counterfeited with clinical trials
and pipeline drugs. For instance, intraocular Fomivirsen has been found to prevent CMV retinitis during clinical trials. Further, the CMV retinitis
market can also be segmented on the basis of available therapeutic treatments into anti-CMV Oral Ganciclovir, anti-CMV Intravenous drug
therapy, anti-CMV Intraocular (local), and anti-HIV Systemic and Retinal Detachment through Vitrectomy. Oral therapy is relatively more
convenient and recommended for peripheral retinitis cases but not for later stages of CMV retinitis when the condition becomes visually
Intravenous therapy treats the infection along with protecting the eye against systemic infection. Furthermore, higher longevity has been observed
with Foscarnet in comparison to Ganciclovir. Intraocular therapy is highly effective in controlling infection, and is relatively less costly than systemic
and superior to intravenous. However, intraocular implants need replacement after a duration of 6-8 months, especially among those having lower
levels of T-helper cell counts. Systemic treatment is directed towards the HIV virus through a combination of reverse transcriptase and protease
inhibitors, which is a highly active anti-retroviral therapy to restore immune system besides raising the T-helper cell counts.
Geographically, North America (U.S and Canada) dominate the CMV Retinitis market followed by Europe as leading manufacturers of CMV
Retinitis are domiciled in these regions having majority of their operations in the local regional markets. However, Asia Pacific, Africa as well as
Latin America would also prove to be the highly profitable markets in the future due to the high prevalence rates for immunodeficiency diseases in
these regions.
Taking into consideration the staggering figures of around 33,400,000 persons living with HIV infection, who are highly susceptible to the CMV
retinitis condition globally, this specialized and niche market is estimated to escalate at a high pace. However, some of the restraints in this
foresighted growth would include the newer anti-HIV medications, which prevent occurrence of this disease. Moreover, since this disease is largely
concentrated to patients with pre-existing conditions such as HIV the overall size of the market will be smaller as CMV retinitis occur in
approximately 46% of the HIV patients in comparison with other common diseases.
Some of the major players that are currently operating in this market include Bausch & Lomb Incorporated, CSL Behring, Emcure Pharms, Ltd.,
Endo Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Hospira, Inc., Luitpold Pharmaceuticals, Inc., Mylan N.V., and Valeant Pharmaceuticals
International, Inc. among others.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies
analyzed under this research report include
 North America
 Asia Pacific
 Europe
 Middle East and Africa
 Latin America
This report provides comprehensive analysis of
 Market growth drivers
 Factors limiting market growth
 Current market trends
 Market structure
 Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming
years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players.
The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value
chain analysis.
Reasons for Buying this Report
 This report provides pin-point analysis for changing competitive dynamics
 It provides a forward looking perspective on different factors driving or restraining market growth
 It provides a six-year forecast assessed on the basis of how the market is predicted to grow
 It helps in understanding the key product segments and their future
 It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
 It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
 It provides distinctive graphics and exemplified SWOT analysis of major market segments
Request Brochure:-
More Pharmaceutical Reports:
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather
and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to
sustain their competitive edge.
Contact Us:Transparency Market Research
90 State Street,
Suite 700,
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: [email protected]
Browse Market Research Blogs:
keshab3   documents Email
File Size
152 KB
market, analysis, retinitis, 2023, cytomegalovirus
Report inappropriate content